{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-022489","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.147408+00:00","generated_at":"2026-06-16T04:12:06.577184+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eterna Therapeutics acquires Exacis Biotherapeutics' IP assets in stock-and-contingent deal","bullets":["Eterna issued 69,343 shares to Exacis at closing; shares subject to 12-month lockup.","Contingent milestone: if market cap hits $100M, additional $2M in shares; at $200M, another $2M in shares.","Eterna to pay Exacis 20% of sublicensing revenue received within 5 years, capped at $45M.","CEO Matthew Angel is co-founder of Factor Bioscience (Exacis parent); director Gregory Fiore is CEO of Exacis; deal approved by audit committee and disinterested directors.","Eterna assumes only post-closing liabilities under the purchased license; Exacis retains other liabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-022489","json":"https://secwatch.observer/filing/0001140361-23-022489.json","markdown":"https://secwatch.observer/filing/0001140361-23-022489.md","text":"https://secwatch.observer/filing/0001140361-23-022489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123022489/0001140361-23-022489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123022489/brhc20052311_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:12:06.577184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}